Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for chronic kidney disease
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Evaluation of Renal Blood Flow in ChronicKidneyDisease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Chronickidneydisease (CKD) is known to be associated with reduced renal blood flow. However, data to-date in humans is limited.In this study, non-invasive arterial spin labeling (ASL) MRI data was acquired in 33 patients with diabetes and stage-3 CKD, and 30 healthy controls.A significantly lower renal blood flow both in cortex (108.4±36.4 vs. 207.3±41.8; p<0.001, d=2.52 (...) to separate healthy and CKD was estimated to be Cor_BF=142.9 and Med_BF=24.1.These results support the use of ASL in the evaluation of renal blood flow in patients with moderate level of CKD. Whether these measurements can identify subjects at risk of progressive CKD requires further longitudinal follow-up.
Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronickidneydisease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronickidneydisease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin concentration
Efficacy of Folic Acid Therapy on the Progression of ChronicKidneyDisease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folic acid therapy on renal outcomes has not been previously investigated in populations without folic acid fortification.To test whether treatment with enalapril and folic acid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronickidney (...) was the progression of CKD, defined as a decrease in eGFR of 30% or more and to a level of less than 60 mL/min/1.73 m2 if the baseline eGFR was 60 mL/min/1.73 m2 or more, or a decrease in eGFR of 50% or more if the baseline eGFR was less than 60 mL/min/1.73 m2; or end-stage renaldisease. Secondary outcomes included a composite of the primary outcome and all-cause death, rapid decline in renal function, and rate of eGFR decline.Overall, 15 104 Chinese adults with a mean (range) age of 60 (45-75) years were
Lipidomic Signature of Progression of ChronicKidneyDisease in the ChronicRenal Insufficiency Cohort Human studies report conflicting results on the predictive power of serum lipids on progression of chronickidneydisease (CKD). We aimed to systematically identify the lipids that predict progression to end-stage kidney disease.From the ChronicRenal Insufficiency Cohort, 79 patients with CKD stage 2 to 3 who progressed to ESKD over 6 years of follow up were selected and frequency-matched
Relationship between occult hepatitis B virus infection and chronickidneydisease in a Chinese population-based cohort Previous studies have revealed inconsistent results regarding the association between occult hepatitis B virus (HBV) infection and chronickidneydisease (CKD). Therefore, we conducted a prospective cohort study to evaluate the association between occult HBV infection and CKD.A total of 4329 adults, aged 46.2 ± 13.7 years, without CKD at baseline were enrolled while undergoing (...) physical examinations. Occult HBV infection was defined as seropositivity for antibody to HBV core antigen. CKD was defined as decreased estimated glomerular filtration rate (eGFR < 60 ml·min-1·1.73 m-2) or presence of proteinuria ≥1+, assessed using a repeated dipstick method. eGFR was computed using the ChronicKidneyDisease Epidemiology Collaboration (CKD-EPI) equation.The prevalence of occult HBV infection was 8.1% (352/4329). During 5 years of follow-up, 165 patients (3.8%) developed CKD
Trends in Prevalence of ChronicKidneyDisease in the United States. Trends in the prevalence of chronickidneydisease (CKD) are important for health care policy and planning.To update trends in CKD prevalence.Repeated cross-sectional study.NHANES (National Health and Nutrition Examination Survey) for 1988 to 1994 and every 2 years from 1999 to 2012.Adults aged 20 years or older.Chronic kidneydisease (stages 3 and 4) was defined as an estimated glomerular filtration rate (eGFR) of 15 to 59 mL (...) /min/1.73 m2, estimated with the ChronicKidneyDisease Epidemiology Collaboration equation from calibrated serum creatinine measurements. An expanded definition of CKD also included persons with an eGFR of at least 60 mL/min/1.73 m2 and a 1-time urine albumin-creatinine ratio of at least 30 mg/g.The unadjusted prevalence of stage 3 and 4 CKD increased from the late 1990s to the early 2000s. Since 2003 to 2004, however, the overall prevalence has largely stabilized (for example, 6.9% prevalence
Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in ChronicKidneyDisease, From the ChronicRenal Insufficiency Cohort Study Levels of fibroblast growth factor 23 (FGF23) are elevated in chronickidneydisease (CKD) and strongly associated with left ventricular hypertrophy, heart failure, and death. Whether FGF23 is an independent risk factor for atrial fibrillation in CKD is unknown.To investigate the association of FGF23 with atrial fibrillation in CKD.Prospective cohort (...) study of 3876 individuals with mild to severe CKD who enrolled in the ChronicRenal Insufficiency Cohort Study between June 19, 2003, and September 3, 2008, and were followed up through March 31, 2013.Baseline plasma FGF23 levels.Prevalent and incident atrial fibrillation.The study cohort comprised 3876 participants. Their mean (SD) age was 57.7 (11.0) years, and 44.8% (1736 of 3876) were female. Elevated FGF23 levels were independently associated with increased odds of prevalent atrial fibrillation
Implantation of Autologous Selected Renal Cells in Diabetic ChronicKidneyDisease Stages 3 and 4â€”Clinical Experience of a â€œFirst in Humanâ€ Study Animal models of chronickidneydisease demonstrate that a redundant population of therapeutically bioactive selected renal cells (SRCs) can be delivered to the kidney through intraparenchymal injection and arrest disease progression. Direct injection of SRCs has been shown to attenuate nuclear factor-κB, which is known to drive tissue (...) inflammation, as well as the transforming growth factor-β-mediated plasminogen activator inhibitor-1 response that drives tissue fibrosis.We present experience from the first-in-human clinical study with SRCs. Seven male type 2 diabetic patients (63 ± 2 years of age) with chronickidneydisease stage 3 to 4 (estimated glomerular filtration rate 25 ± 2 ml/min) were recruited. After blood and urine sampling, iohexol clearance, magnetic resonance imaging, and renal scintigraphy, patients underwent ultrasound
Grape seed powder improves renal failure of chronickidneydisease patients Chronickidneydisease (CKD) is a syndrome characterized by progressive and irreversible deterioration of renal function linked to slow destruction of renal parenchyma, eventually terminating in death when sufficient number of nephrons are damaged. Oxidative stress is commonly observed in CKD patients resulting from an imbalance between overproduction of reactive oxygen species (ROS) and impairment of defence mechanisms (...) . Grape seed extract (GSE) is a polyphenolic mixture exhibiting antioxidant and anti-inflammatory properties. We conducted an interventional pilot study of supplementation with GSE capsules (GSE group, n = 23) or placebo (control group, n = 10) on CKD patients. Blood and urine samples were collected at baseline and after a six-month-long supplementation period to determine some renal function biomarkers, as well as antioxidant, anti-inflammatory and haematological parameters. GSE improved glomerular
Ambulatory Blood Pressure in ChronicKidneyDisease: Ready for Prime Time? Hypertension is common in patients with chronickidneydisease (CKD) and is the most important modifiable risk factor for CKD progression and adverse cardiovascular events in these patients. Diagnosis and successful management of hypertension are critically dependent on accurate blood pressure (BP) measurement. This is most relevant to CKD patients, in whom BP control is difficult to achieve and in whom early (...) antihypertensive treatment is imperative to prevent kidney and cardiovascular complications. Accumulated data indicate that ambulatory blood pressure monitoring (ABPM) is better in detecting hypertension than office BP measurement. ABPM is also a superior prognostic marker compared with office BP and has successfully identified hypertensive CKD patients at increased risk. Additionally, ABPM provides information on circadian BP variation and short-term BP variability, which is associated with cardiovascular
Sodium Excretion and the Risk of Cardiovascular Disease in Patients With ChronicKidneyDisease. Patients with chronickidneydisease (CKD) are at an increased risk of cardiovascular disease (CVD) compared with the general population. Prior studies have produced contradictory results on the association of dietary sodium intake with risk of CVD, and this relationship has not been investigated in patients with CKD.To evaluate the association between urinary sodium excretion and clinical CVD (...) events among patients with CKD.A prospective cohort study of patients with CKD from 7 locations in the United States enrolled in the ChronicRenal Insufficiency Cohort Study and followed up from May 2003 to March 2013.The cumulative mean of urinary sodium excretion from three 24-hour urinary measurements and calibrated to sex-specific mean 24-hour urinary creatinine excretion.A composite of CVD events defined as congestive heart failure, stroke, or myocardial infarction. Events were reported every 6
chronickidneydisease appear to be less able to mount a complete 'adaptive' repair after acute insults, and instead repair maladaptively, with accelerated fibrosis and rates of renal functional decline. This article reviews the epidemiological studies in man that have demonstrated the links between these two processes. We also examine clinical and experimental research in areas of importance to both acute and chronicdisease: acute and chronicrenal injury to the vasculature, the pericyte (...) Acute kidney injury and chronickidneydisease: from the laboratory to the clinic Chronickidneydisease and acute kidney injury have traditionally been considered as separate entities with different etiologies. This view has changed in recent years, with chronickidneydisease recognized as a major risk factor for the development of new acute kidney injury, and acute kidney injury now accepted to lead to de novo or accelerated chronic and end stage kidneydiseases. Patients with existing
Soluble Urokinase Receptor and ChronicKidneyDisease. 26962914 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and ChronicKidneyDisease. 891 10.1056/NEJMc1515787 Hayek Salim S SS Quyyumi Arshed A AA Reiser Jochen J eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9 (...) ):890 26962915 N Engl J Med. 2016 Mar 3;374(9):890 26962916 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962914 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA3
Soluble Urokinase Receptor and ChronicKidneyDisease. 26962915 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and ChronicKidneyDisease. 890 10.1056/NEJMc1515787 Quaglia Marco M University of Piemonte Orientale, Novara, Italy email@example.com. Musetti Claudio C University of Piemonte Orientale, Novara, Italy firstname.lastname@example.org. Cantaluppi Vincenzo V University of Piemonte Orientale (...) , Novara, Italy email@example.com. eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962915 10.1056/NEJMc1515787 10.1056
Soluble Urokinase Receptor and ChronicKidneyDisease. 26962916 2016 03 11 2018 12 02 1533-4406 374 9 2016 03 03 The New England journal of medicine N. Engl. J. Med. Soluble Urokinase Receptor and ChronicKidneyDisease. 890 10.1056/NEJMc1515787 Schumacher Martin M University of Freiburg Medical Center, Freiburg, Germany firstname.lastname@example.org. Wanner Christoph C Würzburg University Clinic, Würzburg, Germany. Beyersmann Jan J University of Ulm, Ulm, Germany. eng Letter Comment United States N (...) Engl J Med 0255562 0028-4793 0 Receptors, Urokinase Plasminogen Activator AIM IM N Engl J Med. 2015 Nov 12;373(20):1916-25 26539835 N Engl J Med. 2016 Mar 3;374(9):891 26962914 Female Glomerular Filtration Rate Humans Kidney physiology Male Receptors, Urokinase Plasminogen Activator blood Renal Insufficiency, Chronic diagnosis 2016 3 11 6 0 2016 3 11 6 0 2016 3 12 6 0 ppublish 26962916 10.1056/NEJMc1515787 10.1056/NEJMc1515787#SA2
subgroups.Chronic kidneydisease was identified by a single measurement at each visit.Overweight and obesity are associated with an increased incidence of CKD in metabolically healthy young and middle-aged participants. These findings show that metabolically healthy obesity is not a harmless condition and that the obese phenotype, regardless of metabolic abnormalities, can adversely affect renal function.None. (...) Metabolically Healthy Obesity and Development of ChronicKidneyDisease: A Cohort Study. The risk for chronickidneydisease (CKD) among obese persons without obesity-related metabolic abnormalities, called metabolically healthy obesity, is largely unexplored.To investigate the risk for incident CKD across categories of body mass index in a large cohort of metabolically healthy men and women.Prospective cohort study.Kangbuk Samsung Health Study, Kangbuk Samsung Hospital, Seoul, South Korea.62
Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronickidneydisease 27733948 2018 11 13 2147-9720 3 3 2016 Sep European journal of rheumatology Eur J Rheumatol Severe hypocalcemia and prolonged QT interval due to denosumab in an elderly woman with rheumatoid arthritis and chronickidneydisease. 144-145 Oiwa Hiroshi H Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan. Mokuda Sho S (...) Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan; Department of Immunology, Hiroshima University School of Biomedical and Health, Hiroshima, Japan. eng Journal Article 2016 01 29 Turkey Eur J Rheumatol 101656068 2147-9720 Dr. Oiwa reports personal fees from Daiichi Sankyo, during the conduct of the study. 2015 07 02 2015 08 01 2016 10 14 6 0 2016 10 14 6 0 2016 10 14 6 1 ppublish 27733948 10.5152/eurjrheum.2015.0049 ejr-3-3-144 PMC5058456 Am J Kidney Dis. 2009 Jun
The modifiers of chronickidneydisease in autosomal dominant polycystic kidneydisease and the role of the endothelin-1 28197495 2019 01 09 2345-4202 5 1 2016 Journal of nephropharmacology J Nephropharmacol The modifiers of chronickidneydisease in autosomal dominant polycystic kidneydisease and the role of the endothelin-1. 24-25 Einollahi Behzad B Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. Lotfiazar Aidin A Nephrology and Urology (...) Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. eng Journal Article 2016 01 12 Iran J Nephropharmacol 101679372 2345-4202 Autosomal dominant polycystic kidneydiseaseChronickidneydisease Endothelin-1 2015 12 27 2016 01 10 2017 2 16 6 0 2017 2 16 6 0 2017 2 16 6 1 epublish 28197495 PMC5297502 Am J Kidney Dis. 1990 Nov;16(5):403-13 2239929 Iran J Kidney Dis. 2014 Jul;8(4):265-77 25001132 Lancet. 2007 Apr 14;369(9569):1287-301 17434405 J Am Soc Nephrol. 2013 May;24(6):1006
). However the frequency of measurement we recommend provides significant benefits in our opinion but has a weak evidence base due to a general lack of studies in this area(1D). This guideline is endorsed by The British Society for Paediatric Endocrinology and Diabetes (BSPED), The British Association for Paediatric Nephrology (BAPN) and The Paediatric Renal Interest Nutrition Group (PRING). Stages of ChronicKidneyDisease (CKD) 14 Stage GFR* Description Management 1 > 90 Normal Renal Function (...) and anthropometric and nutritional measurements in children with mild to moderate renal insufficiency: a report of the Growth Failure in Children with RenalDiseases study. J Paediatr. 1990; 116: S46 – 54 2. Norman LJ, Coleman JE, MacDonald 1A, Thomsett AM, Watson AR: Nutrition and Growth in relation to severity of renaldisease in children, Paediatric Nephrology 2000; 15, 259-65. 3. Kari JA, Gonzalez C, Lederman S, Shaw V, Rees L: Outcome and Growth of Infants with Severe ChronicRenal Failure. Kidney